Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cetuximab for metastatic colorectal cancer (mCRC), from ASCO 2008

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 27 Nov 2008

Views: 16022

Rating:

Save

Professor Carsten Bokemeyer

Categories:
Colorectal & gastro

Related Videos

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Somatic and germline heterogeneity across colorectal cancer patient...

Prof Jeffrey Weitzel - The University of Kansas Cancer Center, Kansas, USA

Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection ( Prof Jeffrey Weitzel - The University of Kansas Cancer Center, Kansas, USA )

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Healthcare System, Florida, USA

GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Healthcare System, Florida, USA )

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal...

Dr Ronan Kelly - Baylor University Medical Center, Texas, USA

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis ( Dr Ronan Kelly - Baylor University Medical Center, Texas, USA )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Lenvatinib plus pembrolizumab versus standard of care for previously treated...

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

More from ecancer